摘要
目的:探讨瑞舒伐他汀联合硫酸氢氯吡格雷对冠心病患者的临床疗效。方法:选择124例经冠状动脉造影确诊为冠心病的患者为研究对象。患者被随机均分为常规治疗组(常规治疗药物,包括硫酸氢氯吡格雷)和联合治疗组(在常规治疗组基础上加用瑞舒伐他汀),两组均治疗2个月。测定、比较两组治疗前后心功能及血清血管紧张素Ⅱ(AngⅡ)、血管内皮生长因子(VEGF)和一氧化氮(NO)水平,比较两组治疗效果。结果:联合治疗组总有效率显著高于常规治疗组(96.77%比83.87%,P=0.015)。与常规治疗组比较,联合治疗组治疗后左室射血分数[(61.89±7.02)%比(68.96±8.23)%]、NO[(75.25±9.45)μmol/L比(82.25±10.22)μmol/L]水平显著升高,而室壁运动评分指数[(1.35±0.39)%比(1.11±0.29)%]、AngⅡ[(102.25±6.93)ng/L比(52.99±5.36)ng/L]、VEGF[(328.25±23.41)ng/L比(228.69±22.69)ng/L]水平显著降低(P均<0.01)。结论:瑞舒伐他汀联合硫酸氢氯吡格雷能有效改善冠心病患者心功能,降低血管紧张素、血管内皮生长因子水平,升高一氧化氮水平,效果显著,值得推广。
Objective: To explore therapeutic effect of rosuvastatin combined clopidogrel bisulfate tablet on patients with coronary heart disease (CHD). Methods: A total of 124 patients, who were diagnosed as CHD by coronary an- giography, were selected, randomly and equally divided into routine treatment group (received routine treatment,including clopidogrel bisulfate tablet) and combined treatment group (received rosuvastatin based on routine treat- ment group), both groups were treated for six months. Cardiac function, serum levels of angiotensin II (Ang Ⅱ), vascular endothelial growth factor (VEGF) and nitric oxide (NO), and therapeutic effect were measured and com- pared between two groups before and after treatment. Results.. Total effective rate of combined treatment group was significantly higher than that of routine treatment group (96.77% vs. 83.87%, P = 0. 015). Compared with routine treatment group after treatment, there were significant rise in left ventricular ejection fraction [61.89±7.02)% vs. (68.96 ±8.23) %] and NO level [(75.25±9.45)μmol/L vs. (82.25±10.22)μmol/L], and significant reductions in wall motion score index[ (1.35±0.39)% vs. (1.11±0.29)%], levels of AngⅡ [ (102.25±6.93) ng/L vs. (52.99±5.36) ng/L] and VEGF [(328.25±23.41) ng/L vs. (228.69±22.69) ng/L] in combined treatment group, P〈0.01 all. Conclusion.. Rosuvastatin combined clopidogrel bisulfate tablet can effectively improve heart function, serum levels of Ang Ⅱ, VEGF and NO in patients with coronary heart disease, the therapeutic effect is significant, which is worth extending.
出处
《心血管康复医学杂志》
CAS
2017年第4期441-444,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
冠心病
瑞舒伐他汀
氯吡格雷
Coronary disease
Rosuvastatin
Clopidogrel